Evidence map›Paper›PMID 19137008›Full record

ArticleOncogene2009

Sprouty4 negatively regulates protein kinase C activation by inhibiting phosphatidylinositol 4,5-biphosphate hydrolysis.

T Ayada, K Taniguchi, F Okamoto, R Kato, S Komune, G Takaesu, A Yoshimura

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Role of SPRY4 in health and disease.Frontiers in oncology · 2024
    Review
  3. Article
  4. SOCS, SPRED, and NR4a: Negative regulators of cytokine signaling and transcription in immune tolerance.Proceedings of the Japan Academy. Series B, Physical and biological sciences · 2021
    Article
  5. Article
  6. Endothelial CaInternational journal of molecular sciences · 2019
    Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. The developing story of Sprouty and cancer.Cancer metastasis reviews · 2014
    Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

T AyadaDivision of Molecular and Cellular Immunology, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan.
K Taniguchi
F Okamoto
R Kato
S Komune
G Takaesu
A Yoshimura
Kyushu University · JPKeio University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sproutys have been shown to negatively regulate growth factor-induced extracellular signal-regulated kinase (ERK) activation, and suggested to be an anti-oncogene. However, molecular mechanism of the suppression has not yet been clarified completely. Sprouty4 inhibits vascular endothelial growth factor (VEGF)-A-induced ERK activation, but not VEGF-C-induced ERK activation. It has been shown that VEGF-A-mediated ERK activation is strongly dependent on protein kinase C (PKC), whereas that by VEGF-C is dependent on Ras. This suggests that Sprouty4 inhibits the PKC pathway more specifically than the Ras pathway. In this study, we confirmed that Sprouty4 suppressed various signals downstream of PKC, such as phosphorylation of MARCKS and protein kinase D (PKD), as well as PKC-dependent nuclear factor (NF)-kappaB activation. Furthermore, Sprouty4 suppressed upstream signals of PKC, such as Ca(2+) mobilization, phosphatidylinositol 4,5-biphosphate (PIP(2)) breakdown and inositol 1,4,5-triphosphate (IP(3)) production in response to VEGF-A. Those effects were dependent on the C-terminal cysteine-rich region, but not on the N-terminal region of Sprouty4, which is critical for the suppression of fibroblast growth factor (FGF)-mediated ERK activation. Sprouty4 overexpression or deletion of the Sprouty4 gene did not affect phospholipase C (PLC) gamma-1 activation, which is an enzyme that catalyzes PIP(2) hydrolysis. Moreover, Sprouty4 inhibited not only VEGF-A-mediated PIP(2) hydrolysis but also inhibited the lysophosphatidic acid (LPA)-induced PIP(2) breakdown that is catalyzed by PLC beta/epsilon activated by G-protein coupled receptor (GPCR). Taken together, Sprouty4 has broader suppression activity for various stimuli than previously thought; it may function as an inhibitor for various types of PLC-dependent signaling as well as for ERK activation.

Indexed as

AnimalsCalciumCells, CulturedEnzyme ActivationExtracellular Signal-Regulated MAP KinasesFibroblast Growth FactorsFibroblastsGenes, rasHumansHydrolysisInositol 1,4,5-TrisphosphateIntracellular Signaling Peptides and ProteinsLysophospholipidsMembrane ProteinsMiceMitogen-Activated Protein KinasesCalciumExtracellular Signal-Regulated MAP KinasesFibroblast Growth FactorsInositol 1,4,5-TrisphosphateIntracellular Signaling Peptides and Proteinslysophosphatidic acidLysophospholipidsMARCKS protein, humanMarcks protein, mouseMembrane ProteinsMitogen-Activated Protein KinasesMyristoylated Alanine-Rich C Kinase SubstrateNerve Tissue ProteinsNF-kappa BPhosphatidylinositol 4,5-DiphosphatePhosphatidylinositolsPhosphoinositide Phospholipase CPhospholipase C betaphospholipase C epsilonProtein Kinase Cprotein kinase DSPRY4 protein, humanSpry4 protein, mouseVascular Endothelial Growth Factor AVEGFA protein, human

Identifiers

PMID19137008
OpenAlexW1973972298

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.